Alkem Laboratories Share Price
Sector: Biotechnology & Drugs
5328.05 +107.05 (2.05%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
5194.45
Today’s High
5396.80
52 Week Low
4409.90
52 Week High
6440.00
5324.00 +103.00 (1.97%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
5192.00
Today’s High
5400.00
52 Week Low
4407.05
52 Week High
6439.90
Key Metrics
- Market Cap (In Cr) 63704.83
- Beta 0.8
- Div. Yield (%) 0.8
- P/B 6.05
- TTM P/E 31.28
- Peg Ratio 6.82
- Sector P/E 24.5
- Open Price 5222
- Prev Close 5221
Alkem Laboratories Analysis
Price Analysis
-
1 Week5.55%
-
3 Months12.24%
-
6 Month-5.5%
-
YTD-7.33%
-
1 Year-1.82%
Risk Meter
- 25% Low risk
- 25% Moderate risk
- 25% Balanced Risk
- 25% High risk
- 25% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 2
- Buy
- 5
- 5
- 5
- 4
- Hold
- 5
- 5
- 5
- 6
- Sell
- 3
- 3
- 3
- 3
- Strong Sell
- 3
- 3
- 3
- 3
- Total
- 17
- 17
- 17
- 18
Alkem Laboratories News
Why India’s top generics players are rushing to launch this diabetes drug
4 min read . 13 Mar 2025BEML, REC, BDL among 20 stocks to trade ex-date for dividend, bonus or split
3 min read . 14 Feb 2025Alkem Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 12667.58
- Selling/ General/ Admin Expenses Total
- 5096.65
- Depreciation/ Amortization
- 299.3
- Other Operating Expenses Total
- 256.98
- Total Operating Expense
- 10681.06
- Operating Income
- 1986.52
- Net Income Before Taxes
- 2023.13
- Net Income
- 1795.77
- Diluted Normalized EPS
- 150.43
- Period
- 2024
- Total Assets
- 15574.9
- Total Liabilities
- 5262.84
- Total Equity
- 10312.06
- Tangible Book Valueper Share Common Eq
- 822.79
- Period
- 2024
- Cashfrom Operating Activities
- 1948.07
- Cashfrom Investing Activities
- -1008.5
- Cashfrom Financing Activities
- -1145.01
- Net Changein Cash
- -207.49
- Period
- 2023
- Total Revenue
- 11599.26
- Selling/ General/ Admin Expenses Total
- 4877.77
- Depreciation/ Amortization
- 310.42
- Other Operating Expenses Total
- 96.33
- Total Operating Expense
- 10320.11
- Operating Income
- 1279.15
- Net Income Before Taxes
- 1304.77
- Net Income
- 984.17
- Diluted Normalized EPS
- 89.9
- Period
- 2023
- Total Assets
- 13756.63
- Total Liabilities
- 4711.34
- Total Equity
- 9045.29
- Tangible Book Valueper Share Common Eq
- 715.32
- Period
- 2023
- Cashfrom Operating Activities
- 1682.5
- Cashfrom Investing Activities
- 112.84
- Cashfrom Financing Activities
- -1760.82
- Net Changein Cash
- 41.62
- Period
- 2022
- Total Revenue
- 10634.19
- Selling/ General/ Admin Expenses Total
- 4240.27
- Depreciation/ Amortization
- 303.96
- Other Operating Expenses Total
- 53.51
- Total Operating Expense
- 8862.68
- Operating Income
- 1771.51
- Net Income Before Taxes
- 1844.28
- Net Income
- 1645.62
- Diluted Normalized EPS
- 137.57
- Period
- 2022
- Total Assets
- 14069.19
- Total Liabilities
- 5431.29
- Total Equity
- 8637.9
- Tangible Book Valueper Share Common Eq
- 682.69
- Period
- 2022
- Cashfrom Operating Activities
- 1111.02
- Cashfrom Investing Activities
- -1435.13
- Cashfrom Financing Activities
- 379.57
- Net Changein Cash
- 57.96
- Period
- 2021
- Total Revenue
- 8865.01
- Selling/ General/ Admin Expenses Total
- 3277.01
- Depreciation/ Amortization
- 274.58
- Other Operating Expenses Total
- 54.83
- Total Operating Expense
- 7195.53
- Operating Income
- 1669.48
- Net Income Before Taxes
- 1842.1
- Net Income
- 1585.02
- Diluted Normalized EPS
- 129.72
- Period
- 2021
- Total Assets
- 11519.26
- Total Liabilities
- 4142.53
- Total Equity
- 7376.73
- Tangible Book Valueper Share Common Eq
- 576.83
- Period
- 2021
- Cashfrom Operating Activities
- 1264.9
- Cashfrom Investing Activities
- -998.54
- Cashfrom Financing Activities
- -271.75
- Net Changein Cash
- -1.72
- Period
- 2020
- Total Revenue
- 8344.36
- Selling/ General/ Admin Expenses Total
- 3310.36
- Depreciation/ Amortization
- 252.76
- Other Operating Expenses Total
- 71.43
- Total Operating Expense
- 7057.36
- Operating Income
- 1287
- Net Income Before Taxes
- 1259.79
- Net Income
- 1127.07
- Diluted Normalized EPS
- 94.42
- Period
- 2020
- Total Assets
- 9945.54
- Total Liabilities
- 3784.87
- Total Equity
- 6160.67
- Tangible Book Valueper Share Common Eq
- 473.7
- Period
- 2020
- Cashfrom Operating Activities
- 585.08
- Cashfrom Investing Activities
- -741.35
- Cashfrom Financing Activities
- 79.15
- Net Changein Cash
- -73.11
- Period
- 2019
- Total Revenue
- 7357.19
- Selling/ General/ Admin Expenses Total
- 3082.65
- Depreciation/ Amortization
- 193.18
- Other Operating Expenses Total
- 58.7
- Total Operating Expense
- 6396.56
- Operating Income
- 960.63
- Net Income Before Taxes
- 954.66
- Net Income
- 760.51
- Diluted Normalized EPS
- 63.98
- Period
- 2019
- Total Assets
- 8208.19
- Total Liabilities
- 2768.85
- Total Equity
- 5439.34
- Tangible Book Valueper Share Common Eq
- 419.4
- Period
- 2019
- Cashfrom Operating Activities
- 779.65
- Cashfrom Investing Activities
- -316.39
- Cashfrom Financing Activities
- -378.94
- Net Changein Cash
- 82.34
- Period
- 2024-12-31
- Total Revenue
- 3374.28
- Selling/ General/ Admin Expenses Total
- 624.81
- Depreciation/ Amortization
- 85.28
- Other Operating Expenses Total
- 785.75
- Total Operating Expense
- 2700.17
- Operating Income
- 674.11
- Net Income Before Taxes
- 731.07
- Net Income
- 625.82
- Diluted Normalized EPS
- 52.34
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 3414.67
- Selling/ General/ Admin Expenses Total
- 610.49
- Depreciation/ Amortization
- 78.91
- Other Operating Expenses Total
- 846.65
- Total Operating Expense
- 2740.75
- Operating Income
- 673.92
- Net Income Before Taxes
- 780.26
- Net Income
- 688.64
- Diluted Normalized EPS
- 57.6
- Period
- 2024-09-30
- Total Assets
- 17117.03
- Total Liabilities
- 5624.18
- Total Equity
- 11492.85
- Tangible Book Valueper Share Common Eq
- 916.28
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 941.79
- Cashfrom Investing Activities
- -897.83
- Cashfrom Financing Activities
- -321
- Net Changein Cash
- -261.05
- Period
- 2024-06-30
- Total Revenue
- 3031.82
- Selling/ General/ Admin Expenses Total
- 602.27
- Depreciation/ Amortization
- 80.48
- Other Operating Expenses Total
- 744.96
- Total Operating Expense
- 2503.66
- Operating Income
- 528.16
- Net Income Before Taxes
- 619.36
- Net Income
- 545.16
- Diluted Normalized EPS
- 45.6
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2935.82
- Selling/ General/ Admin Expenses Total
- 505.83
- Depreciation/ Amortization
- 83.43
- Other Operating Expenses Total
- 920.61
- Total Operating Expense
- 2613.63
- Operating Income
- 322.19
- Net Income Before Taxes
- 367.34
- Net Income
- 293.56
- Diluted Normalized EPS
- 24.55
- Period
- 2024-03-31
- Total Assets
- 15574.9
- Total Liabilities
- 5262.84
- Total Equity
- 10312.06
- Tangible Book Valueper Share Common Eq
- 822.79
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1948.07
- Cashfrom Investing Activities
- -1008.5
- Cashfrom Financing Activities
- -1145.01
- Net Changein Cash
- -207.49
- Period
- 2023-12-31
- Total Revenue
- 3323.87
- Selling/ General/ Admin Expenses Total
- 572.15
- Depreciation/ Amortization
- 69.56
- Other Operating Expenses Total
- 739.59
- Total Operating Expense
- 2685.84
- Operating Income
- 638.03
- Net Income Before Taxes
- 654.9
- Net Income
- 594.96
- Diluted Normalized EPS
- 49.76
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Alkem Laboratories Technical
Moving Average
SMA
- 5 Day5156.98
- 10 Day5080.34
- 20 Day5074.87
- 50 Day4925.66
- 100 Day5029.03
- 300 Day5423.99
Alkem Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Zydus Lifesciences
- 911.4
- 8.4
- 0.93
- 1323.9
- 797.05
- 91556.08
- Abbott India
- 30650
- 89.15
- 0.29
- 31900
- 25260.2
- 65325.27
- Alkem Laboratories
- 5328.05
- 107.05
- 2.05
- 6440
- 4409.9
- 63704.83
- Glaxosmithkline Pharmaceutical
- 2805.75
- -21.85
- -0.77
- 3147.45
- 1924.3
- 47640.33
- Glenmark Pharmaceuticals
- 1438.5
- -8.8
- -0.61
- 1830.05
- 985.6
- 40594.59
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Zydus Lifesciences
- 23.81
- 4.58
- 15.65
- 14.33
- Abbott India
- 45.91
- 15.34
- 32.31
- 18.83
- Alkem Laboratories
- 34.71
- 6.05
- 18.26
- 13.94
- Glaxosmithkline Pharmaceutical
- 51.85
- 24.56
- 29.26
- 16.77
- Glenmark Pharmaceuticals
- -
- 5.21
- 1.61
- 1.43
Alkem Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-May-25
- Audited Results & Final Dividend
- 07-Feb-25
- Quarterly Results & Interim Dividend
- 13-Nov-24
- Quarterly Results
- 09-Aug-24
- Quarterly Results
- 29-May-24
- Audited Results & Final Dividend
- 09-Feb-24
- Quarterly Results & Interim Dividend
- 07-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 19-May-23
- Audited Results & Final Dividend
- 10-Feb-23
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 05-Oct-24
- 05-Sept-24
- POM
- 30-Aug-24
- 29-May-24
- AGM
- 09-Apr-24
- 06-Mar-24
- POM
- 08-Jan-24
- 07-Dec-23
- POM
- 09-Oct-23
- 07-Sept-23
- POM
- 25-Aug-22
- 13-May-22
- AGM
- 14-Feb-22
- 11-Jan-22
- POM
- 27-Aug-21
- 25-May-21
- AGM
- 26-Mar-21
- 22-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 28-Jan-25
- 14-Feb-25
- 14-Feb-25
- 37
- 29-May-24
- 10-Aug-24
- 09-Aug-24
- 5
- 01-Feb-24
- 17-Feb-24
- 16-Feb-24
- 35
- 19-May-23
- 10-Aug-23
- 10-Aug-23
- 10
- 25-Jan-23
- 18-Feb-23
- 17-Feb-23
- 25
- 24-Jan-23
- 18-Feb-23
- 17-Feb-23
- 15
- 13-May-22
- 10-Aug-22
- 08-Aug-22
- 4
- 24-Jan-22
- 12-Feb-22
- 10-Feb-22
- 30
- 25-May-21
- 10-Aug-21
- 09-Aug-21
- 5
- 27-Jan-21
- 13-Feb-21
- 11-Feb-21
- 25


